|LETTER TO THE EDITOR
|Year : 2020 | Volume
| Issue : 3 | Page : 329-330
Comment on “Role of mitomycin C in the management of ocular surface squamous neoplasia”
Bharat Gurnani1, Kirandeep Kaur2
1 Department of Cornea and Refractive Services, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Puducherry, India
2 Department of Pediatric Ophthalmology and Strabismus, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Puducherry, India
|Date of Submission||26-Jul-2020|
|Date of Acceptance||27-Aug-2020|
|Date of Web Publication||23-Dec-2020|
Dr. Kirandeep Kaur
Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Puducherry - 605 007
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Gurnani B, Kaur K. Comment on “Role of mitomycin C in the management of ocular surface squamous neoplasia”. Kerala J Ophthalmol 2020;32:329-30
|How to cite this URL:|
Gurnani B, Kaur K. Comment on “Role of mitomycin C in the management of ocular surface squamous neoplasia”. Kerala J Ophthalmol [serial online] 2020 [cited 2022 Dec 3];32:329-30. Available from: http://www.kjophthal.com/text.asp?2020/32/3/329/304541
We read the article by Menaka et al. with great interest and at the outset, we must congratulate the authors for the important analysis. However, we have few important observations and suggestions to make.
Firstly, the authors have mentioned that “A prospective study was conducted for a period of 1 year at a tertiary care hospital in Chennai.” It will great if the authors mention the time period of the study (year) because during this corona pandemic most of the prospective studies are at halt and if done during this period, the importance of hand hygiene, wearing mask, and social distancing should be highlighted in the study. This needs clarification.
Secondly, the authors have included patients above the age of 40 years only and all systemic comorbidities were excluded. It would be good to know why young patients were excluded, as they form a good chunk of ocular surface squamous neoplasia (OSSN) cases and also there will be less systemic comorbidities.
Thirdly, it will be great to know, whether all patients underwent human immunodeficiency virus TRI-DOT test or they were excluded based on history alone. Moreover, whether anterior segment optical coherence tomography was a part of routine evaluation as it is a very good tool to assess the depth of OSSN apart from ultrasound biomicroscopy. This will be interesting to know for the readers.
Lastly, the authors have used mitomycin C (MMC) for two cycles at an interval of 1 week. At our center, we are using three cycles of MMC 0.04% four times/day for 1-week on and 1-week off regimen along with topical steroids and lubricants.
We totally agree with the authors that the use of topical 0.04% MMC has shown good clinical results without any serious side effects with a very less recurrence rate at the end of 1-year follow-up when used as alternate 7-day courses. More number of large-sample multicentric studies with a longer follow-up period are warranted to substantiate the role of MMC.
The authors would like to thank the management of Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Puducherry.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Menaka C, Perumal V, Shankar R. Role of mitomycin C in the management of ocular surface squamous neoplasia. Kerala J Ophthalmol 2020;32:143-7. [Full text]
Pe'er J. Ocular surface squamous neoplasia. Ophthalmol Clin North Am 2005;18:1-13.
Thomas BJ, Galor A, Nanji AA, El Sayyad F, Wang J, Dubovy SR, et al
. Ultra high-resolution anterior segment optical coherence tomography in the diagnosis and management of ocular surface squamous neoplasia. Ocul Surf 2014;12:46-58.
Chen C, Louis D, Dodd T, Muecke J. Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia. Br J Ophthalmol 2004;88:17-8.